# Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis

> **NCT04610359** · PHASE1 · UNKNOWN · sponsor: **Asan Medical Center** · enrollment: 3 (estimated)

## Conditions studied

- Interstitial Cystitis
- Stem Cell Transplant
- Mesenchymal Stem Cell

## Interventions

- **DRUG:** MR-MC-01

## Key facts

- **NCT ID:** NCT04610359
- **Lead sponsor:** Asan Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-20
- **Primary completion:** 2022-10
- **Final completion:** 2022-12
- **Target enrollment:** 3 (ESTIMATED)
- **Last updated:** 2020-10-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04610359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04610359, "Safety of Human Embryonic Stem Cell (hESC)-Derived Mesenchymal Stem Cells in Interstitial Cystitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04610359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*